SEC Form 4 · accession 0001209191-19-014993
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Asaf Danziger
Officer — Chief Executive Officer · Director
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 27, 2019 | M | 9,260 | $52.90 | A | 233,757 | D | |
| Ordinary SharesF1 | Feb 28, 2019 | M | 903 | $14.37 | A | 234,660 | D | |
| Ordinary SharesF2 | Feb 28, 2019 | S | 903 | $54.395 | D | 233,757 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3 | $0.00 | Feb 27, 2019 | M | 9,260 | D | Feb 27, 2019 | — | Ordinary Shares | 9,260 | 18,518 | D |
| Options to Buy Ordinary SharesF4 | $14.37 | Feb 28, 2019 | M | 903 | D | — | Feb 23, 2025 | Ordinary Shares | 903 | 353,887 | D |
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger.
- F2On February 28, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Danziger, Mr. Danziger sold 903 shares in multiple trades at prices ranging from $54.37 to $54.44. The price reported above reflects the weighted average sale price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.
- F3Fully vested as of the date hereof.
- F4Fully vested and currently exercisable as of the date hereof.